literature

HIV mutation literature information.

HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China.

PMID: 28750025 2017 PloS one

Abstract: M184V was the most frequently found point mutation, conferring resistance to the nucleoside reverse transcriptase inhibitor, while Y181C, G190A, K103N and V179D/E/F were the most frequent point mutations conferring resistance to the non-nucleoside reverse transcriptase inhibitor.

Discussion: In vitro studies have demonstrated that while Y181C/I/V could result in high level resistance to NVP and low level resistance to EFV, G190A led to high level resistance to NVP, and intermediate resistance to EFV.

Discussion: Similarly, Y181C, G190A,

Prevalence of HIV-1 transmitted drug resistance in recently infected, treatment-naive persons in the Southwest of Iran, 2014-2015.

PMID: 28589513 2017 Archives of virology

Abstract: Two participants had non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations, specifically K103N in one individual and K101EK/K103KN/G190AG in the other.

Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans.

PMID: 28553415 2017 The open microbiology journal

Abstract: Six-percent (n=6) had at least one HIVDR mutation, comprising NRTI-associated mutations, (M184V, T69D, T69N and V75I); NNRTI-associated mutations (G190A, K103N, V106M, Y181C) and thymidine analogue associated mutations (D67N, K70R, K219Q, L210W, M41L, T215Y).

Result: One participant had seven mutations, three were TAMs (L210W, T215Y and

PMID: 28472323 2017 The Journal of antimicrobial chemotherapy

Table: G190A

Discussion: Notably, cluster 50 (cluster size 140) and cluster 99-K103N (cluster size 34) remain persistent sub-epidemics harbouring G190A and K103N, respectively.

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

PMID: 28382208 2017 SAGE open medicine

Result: The most frequently observed baseline etravirine RAMs were G190A (18/151), V90I (15/151), A98G (10/151), and K101E (9/151) (Supplementary Figure 1).

Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.

PMID: 28234630 2017 Antiviral therapy

Abstract: The most frequent mutations conferring resistance to rilpivirine were: E138A (n=6) and G190A (n=4).

Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naive persons in rural western Kenya.

PMID: 28178281 2017 PloS one

Table: G190A

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.

PMID: 28129253 2017 Journal of acquired immune deficiency syndromes (1999)

Result: After adjustment, participants on zidovudine at failure were more likely to have T215F, T215Y, M41L, K70R, D67N, L210W, type-1 thymidine analog, type-2 thymidine analog, and any thymidine analogue mutations (TAMs); those on tenofovir to have K65R, K70E, Y115F, and M184I; those on efavirenz to have K103N, P225H, Y188L, and L100I; and those on nevirapine to have Y181C and G190A.

HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China.

PMID: 28114955 2017 AIDS research and therapy

Result: In NNRTI coding regions, K103 N was the most frequent mutation, accounting for 15.9% (34/214), followed by Y181C (11.7%, 25/214), G190A (5.1%, 11/214), and G190S (3.7%, 8/214).

Table: G190A/S

Table: G190A

Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China.

PMID: 28099515 2017 PloS one

Abstract: Among them, 7 polymorphisms (L74I, K103N, V106A, Y181C, G190A, T215I and P225H) were known to be drug resistance mutations, 7 polymorphisms ( Table: G190A

Discussion: The other two non-drug-resistance mutations (E6D and E169D) also had indirect relationship with drug resistance mutations (e.g., E6D:K70R:Q197K; E169D:V179I:G190A), indicating a possible association between these mutations and drug resistance.

Browser Board

Co-occurred Entities

Filtrator